Zerbaxa® (ceftolozane/tazobactam) has received an expanded indication to treat complicated intra-abdominal infections and complicated urinary tract infections, including pyelonephritis, in patients of all ages. It was previously approved for this use only in adults.

• First FDA approved in 2014, Zerbaxa is also indicated to treat adults who have hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia.
• Recommended dosing and the duration of treatment are based on factors such as the patient’s age, weight, renal health, and diagnosis.